Ligand Pharmaceuticals (LGND) Non-Current Deferred Tax Liability (2010 - 2026)

Ligand Pharmaceuticals has disclosed Non-Current Deferred Tax Liability across 14 years of filings, most recently posting $22.6 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $22.6 million, down 23.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.6 million (down 23.03% YoY), and the FY2025 annual result was $36.0 million, down 50.75% from the prior year.
• Non-Current Deferred Tax Liability came in at $22.6 million for Q1 2026 at Ligand Pharmaceuticals, down from $36.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $73.1 million in Q4 2024 to a low of $22.6 million in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $31.6 million (2023), against an average of $35.7 million.
• Across the five-year window, Non-Current Deferred Tax Liability tumbled 57.66% in 2022 and jumped 131.3% in 2024, its largest moves.
• Ligand Pharmaceuticals' Non-Current Deferred Tax Liability stood at $30.6 million in 2022, then increased by 3.29% to $31.6 million in 2023, then surged by 131.3% to $73.1 million in 2024, then tumbled by 50.75% to $36.0 million in 2025, then plunged by 37.22% to $22.6 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $22.6 million (Q1 2026), $36.0 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.